Please login to the form below

Not currently logged in
Email:
Password:

Roche's Silvia Ayyoubi retires

She will step down in March as head of group human resources

Roche Silvia AyyoubiSilvia Ayyoubi is to step down as head of group human resources at Roche in the Swiss pharma firm's annual general meeting in March.

She joined Roche in 1987 and held several positions of growing responsibility in human resources, serving as head of group human resources and a member of its corporate executive committee since 2008.

Christoph Franz, chairman of Roche, said: “I thank Silvia Ayyoubi for the outstanding contributions she has made during her almost 30 years with Roche, the last eight years in her current position.

“Silvia Ayyoubi has created and led an effective global human resources function, enabling Roche to attract and develop the most talented people world-wide.”

Ayyoubi will be succeeded by Cristina Wilbur, who is currently head of human resources for Roche's diagnostics division, based in Basel.

She first joined the company's US operations in 2002 and from 2006 until 2010 was head of human resources for Roche's US diagnostics organisation.

5th February 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics